Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Capivasertib Alone and with Itraconazole in Healthy Subjects
NCT04712396Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of capivasertib in triple negative breast cancer (TNBC), Hormone-Receptor-Positive Breast Cancer and prostate cancer (PCa), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration-time curve from zero to infinity at 48 hours and Maximum observed plasma drug concentration at 48 hours. Started Feb 2021; status: completed.
02
Drugs
capivasertib
03
Conditions
triple negative breast cancer (TNBC)Hormone-Receptor-Positive Breast Cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT04712396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04712396.